Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 164

1.

Establishing Reference Ranges of Hematological Parameters from Malian Healthy Adults.

Kone B, Maiga M, Baya B, Sarro Y, Coulibaly N, Kone A, Diarra B, Sanogo M, Togo A, Goita D, Dembele M, Polis MA, Warfield J, Belson M, Dao S, Orsega S, Murphy RL, Diallo S, Siddiqui S.

J Blood Lymph. 2017;7(1). pii: 154. doi: 10.4172/2165-7831.1000154. Epub 2017 Mar 15.

2.

Clinical characteristics of non-tuberculous mycobacterial pulmonary infections in Bamako, Mali.

Kone B, Sarro YS, Maiga M, Sanogo M, Somboro AM, Diarra B, Togo ACG, Coulibaly N, Dembele BPP, Goita D, Baya B, Kone A, Diabaté S, Polis MA, Belson M, Dao S, Orsega S, Achenbach CJ, Murphy RL, Diallo S, Siddiqui S.

Epidemiol Infect. 2018 Feb;146(3):354-358. doi: 10.1017/S0950268817003090. Epub 2018 Jan 15.

3.

Performance of microscopic observation drug susceptibility for the rapid diagnosis of tuberculosis and detection of drug resistance in Bamako, Mali.

Sanogo M, Kone B, Diarra B, Maiga M, Baya B, Somboro AM, Sarro YS, Togo ACG, Dembele BPP, Goita D, Kone A, M'Baye O, Coulibaly N, Diabate S, Traore B, Diallo MH, Coulibaly YI, Saleeb P, Belson M, Orsega S, Siddiqui S, Polis MA, Dao S, Murphy RL, Diallo S.

Clin Microbiol Infect. 2017 Jun;23(6):408.e1-408.e6. doi: 10.1016/j.cmi.2017.01.004. Epub 2017 Jan 18.

4.

Tuberculosis drug resistance in Bamako, Mali, from 2006 to 2014.

Diarra B, Goita D, Tounkara S, Sanogo M, Baya B, Togo AC, Maiga M, Sarro YS, Kone A, Kone B, M'Baye O, Coulibaly N, Kassambara H, Cisse A, Belson M, Polis MA, Otu J, Gehre F, Antonio M, Dao S, Siddiqui S, Murphy RL, de Jong BC, Diallo S.

BMC Infect Dis. 2016 Nov 28;16(1):714.

5.

Safe and effective sofosbuvir-based therapy in patients with mental health disease on hepatitis C virus treatment.

Tang LS, Masur J, Sims Z, Nelson A, Osinusi A, Kohli A, Kattakuzhy S, Polis M, Kottilil S.

World J Hepatol. 2016 Nov 8;8(31):1318-1326.

6.

Laboratory Response to 2014 Ebola Virus Outbreak in Mali.

Diarra B, Safronetz D, Sarro YD, Kone A, Sanogo M, Tounkara S, Togo AC, Daou F, Maiga AI, Dao S, Rosenke K, Falzarano D, Doumbia S, Zoon KC, Polis M, Siddiqui S, Sow S, Schwan TG, Feldmann H, Diallo S, Koita OA.

J Infect Dis. 2016 Oct 15;214(suppl 3):S164-S168.

7.

Stool microbiome reveals diverse bacterial ureases as confounders of oral urea breath testing for Helicobacter pylori and Mycobacterium tuberculosis in Bamako, Mali.

Maiga M, Cohen K, Baya B, Srikrishna G, Siddiqui S, Sanogo M, Somboro AM, Diarra B, Diallo MH, Mazumdar V, Yoder C, Orsega S, Belson M, Kassambara H, Goita D, Murphy RL, Dao S, Polis M, Diallo S, Timmins GS, Dodd L, Earl AM, Bishai WR.

J Breath Res. 2016 Aug 17;10(3):036012. doi: 10.1088/1752-7155/10/3/036012.

8.

Sofosbuvir and ledipasvir for HIV/HCV co-infected patients.

Rosenthal ES, Kottilil S, Polis MA.

Expert Opin Pharmacother. 2016;17(5):743-9. doi: 10.1517/14656566.2016.1157580. Epub 2016 Mar 16. Review.

9.

Clonally expanded CD4+ T cells can produce infectious HIV-1 in vivo.

Simonetti FR, Sobolewski MD, Fyne E, Shao W, Spindler J, Hattori J, Anderson EM, Watters SA, Hill S, Wu X, Wells D, Su L, Luke BT, Halvas EK, Besson G, Penrose KJ, Yang Z, Kwan RW, Van Waes C, Uldrick T, Citrin DE, Kovacs J, Polis MA, Rehm CA, Gorelick R, Piatak M, Keele BF, Kearney MF, Coffin JM, Hughes SH, Mellors JW, Maldarelli F.

Proc Natl Acad Sci U S A. 2016 Feb 16;113(7):1883-8. doi: 10.1073/pnas.1522675113. Epub 2016 Feb 8.

10.

Effect of HIV co-infection on adherence to a 12-week regimen of hepatitis C virus therapy with ledipasvir and sofosbuvir.

Townsend K, Petersen T, Gordon LA, Kohli A, Nelson A, Seamon C, Gross C, Tang L, Osinusi A, Polis MA, Masur H, Kottilil S.

AIDS. 2016 Jan;30(2):261-6. doi: 10.1097/QAD.0000000000000903.

PMID:
26691547
11.

High adherence to all-oral directly acting antiviral HCV therapy among an inner-city patient population in a phase 2a study.

Petersen T, Townsend K, Gordon LA, Sidharthan S, Silk R, Nelson A, Gross C, Calderón M, Proschan M, Osinusi A, Polis MA, Masur H, Kottilil S, Kohli A.

Hepatol Int. 2016 Mar;10(2):310-9. doi: 10.1007/s12072-015-9680-7. Epub 2015 Nov 26.

12.

Four-Week Direct-Acting Antiviral Regimens in Noncirrhotic Patients With Hepatitis C Virus Genotype 1 Infection: An Open-Label, Nonrandomized Trial.

Kohli A, Kattakuzhy S, Sidharthan S, Nelson A, McLaughlin M, Seamon C, Wilson E, Meissner EG, Sims Z, Silk R, Gross C, Akoth E, Tang L, Price A, Jolley TA, Emmanuel B, Proschan M, Teferi G, Chavez J, Abbott S, Osinusi A, Mo H, Polis MA, Masur H, Kottilil S.

Ann Intern Med. 2015 Dec 15;163(12):899-907. doi: 10.7326/M15-0642. Epub 2015 Nov 24.

PMID:
26595450
13.

Moderate Sustained Virologic Response Rates With 6-Week Combination Directly Acting Anti-Hepatitis C Virus Therapy in Patients With Advanced Liver Disease.

Kattakuzhy S, Wilson E, Sidharthan S, Sims Z, McLaughlin M, Price A, Silk R, Gross C, Akoth E, McManus M, Emmanuel B, Shrivastava S, Tang L, Nelson A, Teferi G, Chavez J, Lam B, Mo H, Osinusi A, Polis MA, Masur H, Kohli A, Kottilil S.

Clin Infect Dis. 2016 Feb 15;62(4):440-447. doi: 10.1093/cid/civ897. Epub 2015 Oct 26.

14.

International Collaborative Research Partnerships: Blending Science with Management and Diplomacy.

Lau CY, Wang C, Orsega S, Tramont EC, Koita O, Polis MA, Siddiqui S.

J AIDS Clin Res. 2014 Dec;5(12). pii: 385.

15.

Ledipasvir and sofosbuvir for hepatitis C genotype 4: a proof-of-concept, single-centre, open-label phase 2a cohort study.

Kohli A, Kapoor R, Sims Z, Nelson A, Sidharthan S, Lam B, Silk R, Kotb C, Gross C, Teferi G, Sugarman K, Pang PS, Osinusi A, Polis MA, Rustgi V, Masur H, Kottilil S.

Lancet Infect Dis. 2015 Sep;15(9):1049-1054. doi: 10.1016/S1473-3099(15)00157-7. Epub 2015 Jul 14.

16.
17.

Tuberculosis specific responses following therapy for TB: Impact of HIV co-infection.

Siddiqui S, Sarro Y, Diarra B, Diallo H, Guindo O, Dabitao D, Tall M, Hammond A, Kassambara H, Goita D, Dembele P, Traore B, Hengel R, Nason M, Warfield J, Washington J, Polis M, Diallo S, Dao S, Koita O, Lane HC, Catalfamo M, Tounkara A.

Clin Immunol. 2015 Jul;159(1):1-12. doi: 10.1016/j.clim.2015.04.002. Epub 2015 Apr 15.

PMID:
25889622
18.

Morbidity and mortality according to latest CD4+ cell count among HIV positive individuals in South Africa who enrolled in project Phidisa.

Maduna PH, Dolan M, Kondlo L, Mabuza H, Dlamini JN, Polis M, Mnisi T, Orsega S, Maja P, Ledwaba L, Molefe T, Sangweni P, Malan L, Matchaba G, Khabo P, Grandits G, Neaton JD.

PLoS One. 2015 Apr 9;10(4):e0121843. doi: 10.1371/journal.pone.0121843. eCollection 2015.

19.

Treatment of hepatitis C virus infection.

Kottilil S, Wright M, Polis MA, Masur H.

Ann Intern Med. 2015 Mar 17;162(6):459. doi: 10.7326/L15-5064-4. No abstract available.

PMID:
25775329
20.

Virologic response following combined ledipasvir and sofosbuvir administration in patients with HCV genotype 1 and HIV co-infection.

Osinusi A, Townsend K, Kohli A, Nelson A, Seamon C, Meissner EG, Bon D, Silk R, Gross C, Price A, Sajadi M, Sidharthan S, Sims Z, Herrmann E, Hogan J, Teferi G, Talwani R, Proschan M, Jenkins V, Kleiner DE, Wood BJ, Subramanian GM, Pang PS, McHutchison JG, Polis MA, Fauci AS, Masur H, Kottilil S.

JAMA. 2015 Mar 24-31;313(12):1232-9. doi: 10.1001/jama.2015.1373.

PMID:
25706232
21.

Virological response after 6 week triple-drug regimens for hepatitis C: a proof-of-concept phase 2A cohort study.

Kohli A, Osinusi A, Sims Z, Nelson A, Meissner EG, Barrett LL, Bon D, Marti MM, Silk R, Kotb C, Gross C, Jolley TA, Sidharthan S, Petersen T, Townsend K, Egerson D, Kapoor R, Spurlin E, Sneller M, Proschan M, Herrmann E, Kwan R, Teferi G, Talwani R, Diaz G, Kleiner DE, Wood BJ, Chavez J, Abbott S, Symonds WT, Subramanian GM, Pang PS, McHutchison J, Polis MA, Fauci AS, Masur H, Kottilil S.

Lancet. 2015 Mar 21;385(9973):1107-13. doi: 10.1016/S0140-6736(14)61228-9. Epub 2015 Jan 13.

22.

HCC surveillance results in earlier HCC detection: results from an Indian cohort.

Kohli A, Murphy AA, Agarwal C, Shivakumar B, Kottilil S, Polis MA, Subramanian GM, Midha V, Goyal O, Desai S, Sood A, Shah S.

Springerplus. 2014 Oct 17;3:610. doi: 10.1186/2193-1801-3-610. eCollection 2014.

23.

Treatment of hepatitis C virus infection: is it time for the internist to take the reins?

Kottilil S, Wright M, Polis MA, Masur H.

Ann Intern Med. 2014 Sep 16;161(6):443-4. doi: 10.7326/M14-0741. No abstract available.

PMID:
25222390
24.

Endogenous intrahepatic IFNs and association with IFN-free HCV treatment outcome.

Meissner EG, Wu D, Osinusi A, Bon D, Virtaneva K, Sturdevant D, Porcella S, Wang H, Herrmann E, McHutchison J, Suffredini AF, Polis M, Hewitt S, Prokunina-Olsson L, Masur H, Fauci AS, Kottilil S.

J Clin Invest. 2014 Aug;124(8):3352-63. doi: 10.1172/JCI75938. Epub 2014 Jul 1.

25.

Short communication: serum-based assay accurately detects single nucleotide polymorphisms of IL28B and SOCS3 in HIV/hepatitis C virus-coinfected subjects.

Shaffer A, Hubbard JJ, Townsend K, Kottilil S, Polis MA, Masur H, Kohli A.

AIDS Res Hum Retroviruses. 2014 Aug;30(8):792-5. doi: 10.1089/AID.2014.0028. Epub 2014 Jul 14.

26.

Inteleukin-23 promotes interferon-α responsiveness in hepatitis C virus/HIV-coinfected patients.

Odigie M, Osinusi A, Barrett L, Townsend K, Wang H, Suffredini AF, Masur H, Polis MA, Kottilil S.

AIDS Res Hum Retroviruses. 2014 Aug;30(8):775-82. doi: 10.1089/AID.2014.0003. Epub 2014 Jun 30.

27.

Comparative efficacy, pharmacokinetic, pharmacodynamic activity, and interferon stimulated gene expression of different interferon formulations in HIV/HCV genotype-1 infected patients.

Osinusi A, Bon D, Nelson A, Lee YJ, Poonia S, Shivakumar B, Cai SY, Wood B, Haagmans B, Lempicki R, Herrmann E, Sneller M, Polis M, Masur H, Kottilil S.

J Med Virol. 2014 Feb;86(2):177-85. doi: 10.1002/jmv.23773. Epub 2013 Oct 26.

PMID:
24166150
28.

Sofosbuvir and ribavirin for hepatitis C genotype 1 in patients with unfavorable treatment characteristics: a randomized clinical trial.

Osinusi A, Meissner EG, Lee YJ, Bon D, Heytens L, Nelson A, Sneller M, Kohli A, Barrett L, Proschan M, Herrmann E, Shivakumar B, Gu W, Kwan R, Teferi G, Talwani R, Silk R, Kotb C, Wroblewski S, Fishbein D, Dewar R, Highbarger H, Zhang X, Kleiner D, Wood BJ, Chavez J, Symonds WT, Subramanian M, McHutchison J, Polis MA, Fauci AS, Masur H, Kottilil S.

JAMA. 2013 Aug 28;310(8):804-11. doi: 10.1001/jama.2013.109309. Erratum in: JAMA. 2013 Nov 13;310(18):1987. Dosage error in article text.

29.

Baseline CD4+ T-cell counts predict HBV viral kinetics to adefovir treatment in lamivudine-resistant HBV-infected patients with or without HIV infection.

Cortez KJ, Proschan MA, Barrett L, Brust DG, Weatherley B, Formentini E, Davey RT, Masur H, Polis MA, Neumann And AU, Kottilil S.

HIV Clin Trials. 2013 Jul-Aug;14(4):149-59. doi: 10.1310/hct1404-149.

30.

Short communication: Interferon/ribavirin treatment for HCV is associated with the development of hypophosphatemia in HIV/hepatitis C virus-coinfected patients.

Funk EK, Shaffer A, Shivakumar B, Sneller M, Polis MA, Masur H, Heytens L, Nelson A, Kwan R, Kottilil S, Kohli A.

AIDS Res Hum Retroviruses. 2013 Sep;29(9):1190-4. doi: 10.1089/AID.2013.0035. Epub 2013 Jun 14.

31.

HIV populations are large and accumulate high genetic diversity in a nonlinear fashion.

Maldarelli F, Kearney M, Palmer S, Stephens R, Mican J, Polis MA, Davey RT, Kovacs J, Shao W, Rock-Kress D, Metcalf JA, Rehm C, Greer SE, Lucey DL, Danley K, Alter H, Mellors JW, Coffin JM.

J Virol. 2013 Sep;87(18):10313-23. doi: 10.1128/JVI.01225-12. Epub 2013 May 15.

32.

Adjuvant host-directed therapy with types 3 and 5 but not type 4 phosphodiesterase inhibitors shortens the duration of tuberculosis treatment.

Maiga M, Ammerman NC, Maiga MC, Tounkara A, Siddiqui S, Polis M, Murphy R, Bishai WR.

J Infect Dis. 2013 Aug 1;208(3):512-9. doi: 10.1093/infdis/jit187. Epub 2013 May 2. Erratum in: J Infect Dis. 2015 Jan 15;211(2):333.

33.

Immune biomarker differences and changes comparing HCV mono-infected, HIV/HCV co-infected, and HCV spontaneously cleared patients.

Kushner LE, Wendelboe AM, Lazzeroni LC, Chary A, Winters MA, Osinusi A, Kottilil S, Polis MA, Holodniy M.

PLoS One. 2013 Apr 4;8(4):e60387. doi: 10.1371/journal.pone.0060387. Print 2013.

34.

ACP Journal Club: a clinical decision-support system with interactive alerts improved CD4 cell count in HIV.

Polis MA.

Ann Intern Med. 2013 Apr 16;158(8):JC11. doi: 10.7326/0003-4819-158-8-201304160-02011. No abstract available.

PMID:
23588764
35.

High interferon-stimulated gene ISG-15 expression affects HCV treatment outcome in patients co-infected with HIV and HCV.

Katsounas A, Hubbard JJ, Wang CH, Zhang X, Dou D, Shivakumar B, Winter S, Schlaak JF, Lempicki RA, Masur H, Polis M, Kottilil S, Osinusi A.

J Med Virol. 2013 Jun;85(6):959-63. doi: 10.1002/jmv.23576.

PMID:
23588721
36.

ACP Journal Club. Preexposure prophylaxis reduced HIV-1 spread in serodiscordant heterosexual couples.

Polis MA.

Ann Intern Med. 2012 Nov 20;157(10):JC5-3. doi: 10.7326/0003-4819-157-10-201211200-02003. No abstract available.

PMID:
23165679
37.

IL28B polymorphism is not associated with HCV protease diversity in patients co-infected with HIV and HCV treated with pegylated interferon and ribavirin.

Osinusi A, Chary A, Winters MA, Naggie S, Masur H, Polis MA, Kottilil S, Holodniy M.

J Med Virol. 2012 Oct;84(10):1522-7. doi: 10.1002/jmv.23376.

38.

Gene expression profiles predict emergence of psychiatric adverse events in HIV/HCV-coinfected patients on interferon-based HCV therapy.

Rasimas J, Katsounas A, Raza H, Murphy AA, Yang J, Lempicki RA, Osinusi A, Masur H, Polis M, Kottilil S, Rosenstein D.

J Acquir Immune Defic Syndr. 2012 Jul 1;60(3):273-81. doi: 10.1097/QAI.0b013e31824c17c4. Erratum in: J Acquir Immune Defic Syndr. 2012 Aug 15;60(5):e122.

39.

Failure to recognize nontuberculous mycobacteria leads to misdiagnosis of chronic pulmonary tuberculosis.

Maiga M, Siddiqui S, Diallo S, Diarra B, Traoré B, Shea YR, Zelazny AM, Dembele BP, Goita D, Kassambara H, Hammond AS, Polis MA, Tounkara A.

PLoS One. 2012;7(5):e36902. doi: 10.1371/journal.pone.0036902. Epub 2012 May 16.

40.

ITPA gene polymorphisms significantly affect hemoglobin decline and treatment outcomes in patients coinfected with HIV and HCV.

Osinusi A, Naggie S, Poonia S, Trippler M, Hu Z, Funk E, Schlaak J, Fishbein D, Masur H, Polis M, Kottilil S.

J Med Virol. 2012 Jul;84(7):1106-14. doi: 10.1002/jmv.23302.

41.

Molecular strain typing of Mycobacterium tuberculosis complex in Bamako, Mali.

Traore B, Diarra B, Dembele BP, Somboro AM, Hammond AS, Siddiqui S, Maiga M, Kone B, Sarro YS, Washington J, Parta M, Coulibaly N, M'baye O, Diallo S, Koita O, Tounkara A, Polis MA.

Int J Tuberc Lung Dis. 2012 Jul;16(7):911-6. doi: 10.5588/ijtld.11.0397. Epub 2012 Apr 9.

PMID:
22508197
42.

Dysregulation of innate immunity in hepatitis C virus genotype 1 IL28B-unfavorable genotype patients: impaired viral kinetics and therapeutic response.

Naggie S, Osinusi A, Katsounas A, Lempicki R, Herrmann E, Thompson AJ, Clark PJ, Patel K, Muir AJ, McHutchison JG, Schlaak JF, Trippler M, Shivakumar B, Masur H, Polis MA, Kottilil S.

Hepatology. 2012 Aug;56(2):444-54. doi: 10.1002/hep.25647. Epub 2012 Jul 2.

43.

CCL5 mRNA is a marker for early fibrosis in chronic hepatitis C and is regulated by interferon-α therapy and toll-like receptor 3 signalling.

Katsounas A, Trippler M, Wang B, Polis M, Lempicki RA, Kottilil S, Gerken G, Schlaak JF.

J Viral Hepat. 2012 Feb;19(2):128-37. doi: 10.1111/j.1365-2893.2011.01503.x. Epub 2011 Nov 21.

PMID:
22239502
44.

ACP Journal Club. Early antiretroviral therapy reduced HIV-1 transmission in serodiscordant couples.

Polis MA.

Ann Intern Med. 2011 Dec 20;155(12):JC6-8. doi: 10.7326/0003-4819-155-12-201112200-02008. No abstract available.

PMID:
22184709
45.

HIV/HCV-coinfected natural viral suppressors have better virologic responses to PEG-IFN and ribavirin than ARV-treated HIV/HCV patients.

Sidique N, Kohli A, Shivakumar B, Migueles S, Subramanian GM, Naggie S, Polis MA, Masur H, Kottilil S.

J Acquir Immune Defic Syndr. 2011 Oct 1;58(2):e38-40. doi: 10.1097/QAI.0b013e31822d463f. No abstract available.

46.

The role of locomotor posture and experience on handedness and footedness in infancy.

Berger SE, Friedman R, Polis MC.

Infant Behav Dev. 2011 Jun;34(3):472-80. doi: 10.1016/j.infbeh.2011.05.003. Epub 2011 Jun 17.

PMID:
21684008
47.

Cumulative viral load and virologic decay patterns after antiretroviral therapy in HIV-infected subjects influence CD4 recovery and AIDS.

Marconi VC, Grandits G, Okulicz JF, Wortmann G, Ganesan A, Crum-Cianflone N, Polis M, Landrum M, Dolan MJ, Ahuja SK, Agan B, Kulkarni H; Infectious Disease Clinical Research Program (IDCRP) HIV Working Group.

PLoS One. 2011;6(5):e17956. doi: 10.1371/journal.pone.0017956. Epub 2011 May 20.

48.

Twice-weekly pegylated interferon-α-2a and ribavirin results in superior viral kinetics in HIV/hepatitis C virus co-infected patients compared to standard therapy.

Murphy AA, Herrmann E, Osinusi AO, Wu L, Sachau W, Lempicki RA, Yang J, Chung TL, Wood BJ, Haagmans BL, Kottilil S, Polis MA.

AIDS. 2011 Jun 1;25(9):1179-87. doi: 10.1097/QAD.0b013e3283471d53. Erratum in: AIDS. 2011 Nov 13;25(17):2195. Chung, Tei L [corrected to Chung, Tje L].

49.

Early postseroconversion CD4 cell counts independently predict CD4 cell count recovery in HIV-1-postive subjects receiving antiretroviral therapy.

Kulkarni H, Okulicz JF, Grandits G, Crum-Cianflone NF, Landrum ML, Hale B, Wortmann G, Tramont E, Polis M, Dolan M, Lifson AR, Agan BK, Ahuja SK, Marconi VC.

J Acquir Immune Defic Syndr. 2011 Aug 15;57(5):387-95. doi: 10.1097/QAI.0b013e3182219113.

50.

HCV in peripheral blood mononuclear cells are predominantly carried on the surface of cells in HIV/HCV co-infected individuals.

Natarajan V, Kottilil S, Hazen A, Adelsberger J, Murphy AA, Polis MA, Kovacs JA.

J Med Virol. 2010 Dec;82(12):2032-7. doi: 10.1002/jmv.21906.

PMID:
20981790

Supplemental Content

Support Center